Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hi All
This report is building on other research already published about waning antibodies protection. Of critical note in this report is that this study didn’t consider Delta. We know this variant can evade and reduce efficacy and effectiveness of the vaccines.
The world is in desperate need of alternatives as the Northern Hemisphere enters into winter.
COVID-19: Protection from coronavirus vaccines wanes within six months, study suggests | UK News | Sky News
https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fnews.sky.com%2Fstory%2Fcovid-19-protection-from-coronavirus-vaccines-wanes-within-six-months-study-suggests-12390006&data=04%7C01%7C%7Cae3bafa59da94828535d08d9679acd82%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637654736835614484%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=m9Y3CrUb1y5flWuCPK%2FsjxD2qE%2BjU0NqWMLEmFJcllU%3D&reserved=0
GLA
GSK are running out of time......
https://endpts.com/one-of-glaxosmithklines-top-cancer-drug-prospects-goes-down-in-3rd-straight-setback-leaving-a-4b-deal-on-life-support/
Reported on Endpoints
Looks like J&J will now walk away from the kinase inhibitor.
https://endpts.com/theravance-takes-a-gut-punch-as-jj-partnered-jak-drug-flops-key-test-in-ulcerative-colitis/
Hi All - crazy couple of days to close the week and clearly some manipulation to fill an order, that ‘unknown’ late trade is likely the cause.
In any case, no bad news and no change in the science. Just a little closer to the next bit of news.
Be prepared for more MM shenanigans next week
GLA
Hi All - being reported on Sky News
The UK has approved its first drug that uses Monoclonal antibodies to fight coronavirus.
Reonapreve, developed by the pharmaceutical firms Regeneron and Roche, uses Monoclonal antibodies, which are man-made proteins that act like natural human antibodies to fight infection.
Regulator - the Medicines and Healthcare products Regulatory Agency (MHRA) - said the clinical trial data they had assessed has shown Ronapreve may be used to prevent infection, treat symptoms of acute coronavirus and can reduce the likelihood of being admitted to hospital due to the virus.
Trials took place before widespread vaccination and before the emergence of virus variants.
Japan was the first country to licence the drug back in July, but the US, EU and other nations have now followed suit.
Health Secretary Sajid Javid said approval of the first drug designed specifically for coronavirus in the country is "fantastic news" and he hoped it could be rolled out for patients on the NHS "as soon as possible".
https://news.sky.com/story/covid-news-live-imminent-decision-on-who-should-get-booster-vaccine-amid-herd-immunity-blow-from-delta-study-12382799?inApp=true
GLA
Hi All
IMHO the most critical issue to lock in for our first in human trials will be the selection of an indication to treat. The patent listed over 30 autoimmune indications that could be treated. This will need locking in so as to design the trials, recruiting of cohorts, optimum locations and setting of endpoints. All before the Clinical Trials Application can be filed.
Therefore, I assume that it will be busy down in SAR HQ getting all the details worked through. They will certainly be selecting an indication that they can confidently prove SDC-1801 will be efficacious and effective with. However, this also needs to be ideally an indication with unmet needs or large demand thus making the trial and its potential success more significant when considering future licensing or takeover.
We have been given a timeline and you can be assured SAR will be on point to get the trials bullet proof - best in class!!
GLA
USA starting to notice
https://www.wsj.com/articles/florida-texas-turn-to-antibody-treatments-as-covid-19-surges-11629284400
Another factor to consider is that 9 months after starting vaccinations, a 3rd ‘booster’ is now required obviously due to waning antibodies and more prevalent mutations.
The government’s of the world need to expedite the search for alternative therapeutics for covid, vaccines alone are clearly not the solution.
IMHO - won’t be too much longer before our being superior to dexamethasone and baricitinib (as TM says ‘exciting and differentiated’ compounds) becomes widely understood and rolled into fast track trials.
GLA
Hi All
Reported on Sky News - Antibodies data should be taken with a 'large pinch of salt', scientist says
Earlier we reported how England has the highest percentage (among the home nations) of adults testing positive for COVID-19 antibodies with 94.2% - while Northern Ireland has the lowest with 90.1%, according to the Office for National Statistics.
Dr Simon Clarke, associate professor in cellular microbiology at the University of Reading, has said people should avoid assuming antibodies mean someone is protected against the virus.
Dr Clarke said: "In the UK currently around 1 in 75 people has the virus, so the latest datasets on antibodies and what they mean for immunity, should be taken with a large pinch of salt.
"The assumption that antibodies would mean that someone is protected from infection or reinfection was one of the biggest mistakes made at the start of the pandemic.
"Quite simply, we still don't yet know what it takes to provide complete protection against COVID-19."
Well, we all know a good candidate that should be entering trials very soon.
GLA
Spot on Afham
I recall the lead in to the Sierra deal, it must have been tough negotiations with CPF/Pronai so in the meantime SAR stuck in the CTA and got approved with a start date, recruitment started and the next we know a license deal pops out.
Could be a similar play now with prospective partners.......applying for CTA will push the negotiations into a more urgent delivery phase.
GLA
Matador
It’s good........the lack of increase in viral load is good as the more viral load the greater the immune response or cytokine storm. Our drug knock the cytokine storm out and actually decreases viral load in an antiviral mechanism. Double whammy!
ATB